CiVi Biopharma (Aurlumyn) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 1

CiVi Biopharma (Aurlumyn) General Information

Description

Developer of prostacyclin mimetic intended to treat severe frostbite in adults. The company offers a novel therapeutic approach, enabling patients to reduce the risk of digit amputations.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Corporate Office
  • MD
  • United States
Primary Industry
Pharmaceuticals
Acquirer
SERB Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • MD
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CiVi Biopharma (Aurlumyn) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CiVi Biopharma (Aurlumyn)‘s full profile, request access.

Request a free trial

CiVi Biopharma (Aurlumyn) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CiVi Biopharma (Aurlumyn)‘s full profile, request access.

Request a free trial

CiVi Biopharma (Aurlumyn) FAQs

  • Where is CiVi Biopharma (Aurlumyn) headquartered?

    CiVi Biopharma (Aurlumyn) is headquartered in MD.

  • What industry is CiVi Biopharma (Aurlumyn) in?

    CiVi Biopharma (Aurlumyn)’s primary industry is Pharmaceuticals.

  • Is CiVi Biopharma (Aurlumyn) a private or public company?

    CiVi Biopharma (Aurlumyn) is a Private company.

  • What is CiVi Biopharma (Aurlumyn)’s current revenue?

    The current revenue for CiVi Biopharma (Aurlumyn) is .

  • Who are CiVi Biopharma (Aurlumyn)’s investors?

    CiVi Biopharma has invested in CiVi Biopharma (Aurlumyn).

  • When was CiVi Biopharma (Aurlumyn) acquired?

    CiVi Biopharma (Aurlumyn) was acquired on 21-Oct-2024.

  • Who acquired CiVi Biopharma (Aurlumyn)?

    CiVi Biopharma (Aurlumyn) was acquired by SERB Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process